Adicet Bio Announces Completion of Last Patient Visit for prula-cel Study

What Happened
Adicet Bio, Inc. (ACET) filed a Form 8-K (Item 7.01) on September 1, 2026 to disclose a press release titled “Adicet Bio Announces Completion of Last Patient Visit for Planned Analysis of prula-cel (formerly ADI-001) Study in Patients with Systemic Lupus Erythematosus With or Without Lupus Nephritis and Provides Corporate Update.” The company reported that the last patient visit for the prula-cel clinical study has been completed, and the press release is furnished as Exhibit 99.1 to the 8-K.

Key Details

• Filing date: September 1, 2026 (Form 8-K, Item 7.01, Regulation FD disclosure).
• Program: prula-cel (formerly ADI-001) study in patients with systemic lupus erythematosus (SLE), with or without lupus nephritis.
• Milestone: Completion of the last patient visit for the planned analysis.
• Exhibit and signature: Press release furnished as Exhibit 99.1; 8-K signed by CFO Nick Harvey.

Why It Matters
Completion of the final patient visit is a required step before the company can perform its planned analysis of the study data; this milestone typically precedes any formal data readout or related corporate updates. The 8-K is a Regulation FD disclosure, meaning the company publicly released this material clinical update; investors should review the linked press release (Exhibit 99.1) for any timeline or additional details the company provided. The filing does not report financial results or executive changes.